Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib combination platform study in myelofibrosis
NL-OMON52828Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib, siremadlin, crizanlizumab, sabatolimab, rineterkib and 1 more in myelofibrosis (MF) (14 arms), sponsored by Novartis. Primary endpoints: Hemoglobin change at end of Cycle 6, Spleen imaging change and 1 more. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON52828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52828.